Description
Angiogenesis, the growth of new vessels from preexisting vasculature, is a critical step in tumor
progression [1]. The tyrosine kinase Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is
a crucial mediator in angiogenesis since the VEGF, excreted by the tumor cells, binds to it
activating several signaling pathways involved in cell survival and proliferation [2]. Recently
thienopyridine derivatives showed to be promising inhibitors of the tyrosine kinase domain of
VEGFR2 [3,4]. In this work new N-[3-(thieno[3,2-b]pyridine-7-ylthio)phenyl]benzamides were
prepared as potential VEGFR2 inhibitors suggested by rational design, as presented below.
; Begouin, Agathe 
